Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs.
Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD).
It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications.
The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions.
It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications.
The company was founded in 2005 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | -0.31 Increased by 0.00% | -0.11 Decreased by -181.82% |
| Feb 29, 24 | -0.02 Increased by +93.55% | -0.09 Increased by +77.78% |
| Nov 14, 23 | -0.25 Increased by +3.85% | -0.29 Increased by +13.79% |
| Aug 7, 23 | -0.29 Increased by 0.00% | -0.35 Increased by +17.14% |
| May 11, 23 | -0.31 Increased by +3.13% | -0.32 Increased by +3.13% |
| Mar 15, 23 | -0.31 Decreased by -19.23% | -0.33 Increased by +6.06% |
| Nov 10, 22 | -0.26 Decreased by -52.94% | -0.29 Increased by +10.34% |
| Aug 10, 22 | -0.29 Decreased by -38.10% | -0.25 Decreased by -16.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 6.19 M Increased by +288.66% | -6.39 M Decreased by -2.01% | Decreased by -103.31% Increased by +73.75% |
| Jun 30, 23 | 3.92 M Increased by +N/A% | -7.37 M Decreased by -6.81% | Decreased by -188.04% Decreased by N/A% |
| Mar 31, 23 | 2.99 M Increased by +N/A% | 408.67 M Increased by +5.34 K% | Increased by +13.68 K% Decreased by N/A% |
| Dec 31, 22 | 957.35 K Decreased by -99.61% | -7.83 M Decreased by -26.43% | Decreased by -817.55% Decreased by -32.21 K% |
| Sep 30, 22 | 1.59 M Increased by +N/A% | -6.26 M Decreased by -59.33% | Decreased by -393.60% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by -100.00% | -6.90 M Decreased by -45.25% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by -100.00% | -7.80 M Decreased by -51.49% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 244.65 M Increased by +422.96 K% | -6.19 M Decreased by -48.17% | Decreased by -2.53% Increased by +99.96% |